Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled...

Area of Science:

• Neuroscience
• Psychiatry
• Pediatrics

Background:

• Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children.
• Objective assessment of ADHD symptoms is crucial for treatment efficacy evaluation.
• Computer-based continuous performance tests (cb-CPT) combined with motion-tracking (MT) offer objective measures of attention and hyperactivity.

Purpose of the Study:

• To assess the efficacy of atomoxetine (ATX) in treating ADHD symptoms in children aged 6-12 years.
• To evaluate ATX's effect on objective measures obtained from a combined computer-based continuous performance test (cb-CPT) and motion-tracking (MT) device.
• To compare ATX treatment with placebo over an 8-week period.

Main Methods:

• A randomized, double-blind, placebo-controlled, 2-arm study.
• Participants (6-12 years) received either ATX (titrated to 1.2 mg/kg/day) or placebo for 8 weeks.
• Primary outcome: cb-CPT/MT standard scores; Secondary outcomes: ADHD Rating Scale (ADHD-RS), Weekly Ratings of Evening and Morning Behavior (WREMB), and Clinical Global Impression - Severity-ADHD (CGI-S-ADHD).

Main Results:

• Atomoxetine significantly reduced all measured cb-CPT/MT q-scores compared to placebo (P < 0.001) with large effect sizes for movement area (ES=1.08) and microevents (ES=1.00).
• Significant improvements were observed in ADHD-RS (total score ES=1.30), WREMB (total score ES=1.00), and CGI-S-ADHD (ES=1.11) scores favoring ATX.
• No significant differences in baseline characteristics were noted between the ATX and placebo groups.

Conclusions:

• Atomoxetine effectively reduces ADHD-related symptoms in children aged 6-12.
• The combination of cb-CPT and MT provides sensitive and objective measures for evaluating ADHD treatment efficacy.
• ATX demonstrates significant clinical benefits across objective performance measures and clinician-rated symptom scales.